We have some good news to share on National Institutes of Health funding for FSHD. As part of the FSH Society’s committee work in Washington, DC, we recently received FY2015… Read More »
NIH funding for Facioscapulohumeral muscular dystrophy sets new record
FSH Society newly awarded grants
The FSH Society has awarded $598,242 in research funds from its August 2015 grant submission cycle. Details of the funded projects can be viewed on this page. These proposals received highest marks from… Read More »
Ultragenyx Pharmaceutical to sponsor FSHD drug development project
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Saint Louis University’s (SLU) Center for World Health and Medicine, announced that they… Read More »
Whole-Body MRI Yields New Insights
By June Kinoshita (from FSH Watch Fall 2015 issue) Click on image below to view full size. In 2013-2014, the FSH Society funded a study led by Doris Leung, MD,… Read More »
Acceleron plans to launch Phase 2 FSHD trial this year
According to a Boston Business Journal story, Cambridge, Massachusetts-based biotech Acceleron Pharma has plans to test its ACE-083 compound in facioscapulohumeral muscular dystrophy patients in a phase 2 clinical trial later… Read More »